Statement of disclosure
Since December 1, 2021, in compliance with the HSE Policy on the marketing of breastmilk substitutes for the Public Health Service, IFAN no longer receives any funding or financial support from industry, pharma or commercial enterprises.
IFAN acknowledges that finance in the form of unrestricted educational support was required in order for its educational and professional aims and objectives to be achieved. IFAN is grateful for the generous support that was provided by members of industry and pharma from 2012-November 2021. During that time IFAN was committed to best practice with regard to interactions with industry and pharma to ensure that committee member’s professional independence of judgement is not affected by receipt of financial support.
All financial support received by IFAN from industry & pharma was administered by IFAN’s unrestricted Education and Development Funds without influence.
In the past, Committee members have attended educational meetings funded by commercial enterprises and have received speakers fees. They have had complete control over lecture content which is based on evidence based information independent of influence.
IFAN declares that its officers’ and members’ independence of judgement is the basis of its advocacy and educational roles and is not influenced by the financial support received. Any views expressed in IFAN’s literature, website or presentations are sincerely held. If any person identifies any conflict or ambiguity IFAN will address the issue immediately, and will publish any clarifications or alterations required.